Affimed Therapeutics AG expands clinical development team
In preparation for the clinical entry of its first product candidate Affimed Therapeutics AG expands its development team with an experienced expert. Effective immediately, Dr Christian Hucke takes over responsibility for planning and implementation of the clinical development programs at Affimed. Dr Hucke joins Affimed from Grünenthal GmbH.
Christian Hucke has long-term experience in conception and management of clinical studies. At Grünenthal he had the overall responsibility for a worldwide Phase-III-Study in pain therapy of cancer patients as well as a Proof-of-Concept-Phase-II-Study against diabetic polyneuropathy. Previously, Dr Hucke worked in clinical drug development at PAION Deutschland GmbH and the ClinPharmCologne TROPON GmbH. In the course of his various activities he was responsible for more than 12 Phase-I, II- and III-Studies in diverse indications. Christian Hucke is a doctor in biology with focus on immunology. After graduating and obtaining a doctorate degree in Düsseldorf he worked at the institute of Medical Microbiology at the Heinrich-Heine University of Düsseldorf.
Dr Rolf H. Günther, CEO of Affimed, commented: "The year 2010 will be a very important and decisive year for Affimed: both our lead-products will enter the clinic in 2010. In this crucial phase, Christian Hucke will hold a key position in our development team."
Organizations
Other news from the department people

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Beer. Soup. Barley's next great use? A medical imaging drink

Forest Discovery: Trees Trade Carbon Among Each Other
Eppendorf with new CEO dual leadership - Former CEO, Thomas Bachmann, left the company

Dunn Labortechnik celebrates its 30th anniversary
Growing Fuel and Medicine: Advancing Biofuels and Plant-Produced Therapeutics - Scientists from WPI and the Arkansas Bioscience Institute Present their Latest Research on Cellulosic

Cell-free quest for new antibiotics - A new method combines synthetic biology with artificial intelligence
STA Pharmaceutical to open new transition metal catalysis center

And the winner is …. cancer research
